StockData
NRX Pharmaceuticals, Inc. logo

NRX Pharmaceuticals, Inc. (NRXP) stock

NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.80+0.35 (+14.29%)

Close on Nov 18, 2026Market cap $121.23MP/E –Yield –

NRX Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

NRX Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$19.90M. For fiscal 2025 it was -$16.22M. The highest annual figure on record is -$713.19K in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$16.22M–
FY2024Dec 31, 2024-$18.50M–
FY2023Dec 31, 2023-$27.84M–
FY2022Dec 31, 2022-$44.34M–
FY2021Dec 31, 2021-$115.80M–
FY2020Dec 31, 2020-$51.39M–
FY2019Dec 31, 2019-$713.19K–
FY2018Dec 31, 2018-$1.01M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.51M–
Q1 FY2026Mar 31, 2026-$4.74M–
Q4 FY2025Dec 31, 2025-$4.62M–
Q3 FY2025Sep 30, 2025-$4.02M–
Q2 FY2025Jun 30, 2025-$3.73M–
Q1 FY2025Mar 31, 2025-$3.85M–
Q4 FY2024Dec 31, 2024-$2.43M–
Q3 FY2024Sep 30, 2024-$3.02M–
Q2 FY2024Jun 30, 2024-$7.05M–
Q1 FY2024Mar 31, 2024-$6.00M–
Q4 FY2023Dec 31, 2023-$4.41M–
Q3 FY2023Sep 30, 2023-$5.81M–
Q2 FY2023Jun 30, 2023-$8.19M–
Q1 FY2023Mar 31, 2023-$3.85M–
Q4 FY2022Dec 31, 2022-$9.89M–
Q3 FY2022Sep 30, 2022-$9.14M–
Q2 FY2022Jun 30, 2022-$9.60M–
Q1 FY2022Mar 31, 2022-$15.71M–
Q4 FY2021Dec 31, 2021-$52.98M–
Q3 FY2021Sep 30, 2021-$20.10M–
Q2 FY2021Jun 30, 2021-$17.12M-16430.1%
Q1 FY2021Mar 31, 2021-$25.61M–
Q4 FY2020Dec 31, 2020-$45.12M–
Q3 FY2020Sep 30, 2020-$5.15M–
Q2 FY2020Jun 30, 2020$104.82K–
Q1 FY2020Mar 31, 2020-$119.30K–
Q4 FY2019Dec 31, 2019-$190.96K–
Q3 FY2019Sep 30, 2019-$183.31K–
Q2 FY2019Jun 30, 2019-$175.74K–
Q1 FY2019Mar 31, 2019-$163.18K–
Q4 FY2018Dec 31, 2018-$322.08K–
Q3 FY2018Sep 30, 2018-$220.24K–
Q2 FY2018Jun 30, 2018-$271.81K–
Q1 FY2018Mar 31, 2018-$192.37K–
Q4 FY2017Dec 31, 2017-$134.48K–

More NRX Pharmaceuticals figures

See a number that looks wrong?